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Abstract
Background: The role of angiogenesis in the pathogenesis of renal cell carcinoma is well recognized, however,
the influence of tumor cells in this activity has not yet been fully clarified. The aim of this study was to analyze the
expression of hypoxia inducible factor-1α (HIF-1α), a regulatory factor of angiogenic switch, in comparison to
vascular endothelial growth factor A and C (VEGF-A and VEGF-C), recognized to be involved in blood and lymph
vessel neoangiogenesis, with potential association in the prognosis of patients with renal cell carcinoma.
Methods: Ninety-four patients with diagnosis of clear cell renal cell carcinomas (CCRCC), all clinicopathological
characteristics and overall survival were unrolled in this study. Immunohistochemicaly VEGF-A, VEGF-C, HIF-1α
and Ki67 were detected on tumor cells and the staining was performed on tissue microarrays (TMA). The staining
was evaluated as a percentage of cytoplasmic or nuclear positive tumor cells.
Results:  Variable expression of all three proteins was confirmed. Both angiogenic factors demonstrated
perimembranous or diffuse cytoplasmic staining, with diffuse pattern positively associated (p < 0.001). Nuclear
HIF-1α expression (nHIF-1α) showed inverse correlation with diffuse cytoplasmic VEGF-A (p = 0.002) and VEGF-
C (p = 0.053), while cytoplasmic HIF-1α expression (cHIF-1α) showed positive correlation with diffuse staining
of both angiogenic factors (p < 0.001; p < 0.001, respectively). In comparison to clinicopathological characteristics,
a higher nuclear grade (p = 0.006; p < 0.001, respectively), larger tumor size (p = 0.009; p = 0.015, respectively),
higher stage (p = 0.023; p = 0.027, respectively) and shorter survival (p = 0.018; p = 0.024, respectively) were
associated with overexpression of cHIF-1α and diffuse cytoplasmic VEGF-A expression. In contrary,
overexpression of nHIF-1α was associated with better diagnostic parameters i.e. lower nuclear grade (p = 0.006),
smaller tumor size (p = 0.057), and longer survival (p = 0.005).
Conclusion: Overexpression of VEGF-A and cHIF-1α in tumor cells highlights a more aggressive subtype of
CCRCC that might have some clinical implications. The significance of nHIF-1α expression associated with better
differentiated tumors should be further elucidated.
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Background
Angiogenesis plays an important role in the development,
progression and dissemination of human tumors [1]. In
the last decade, many angiogenic factors and their recep-
tors have been shown to be expressed in renal cell carci-
noma (RCC) [2]. Among three dominating types of RCC,
clear cell RCC (CCRCC) is generally more vascularized
than the papillary and chromophobe types [3,4]. This vas-
cularization is most likely due to the biallelic loss of the
von Hippel Lindau (VHL) tumor suppressor gene which is
associated with 50–80% of sporadic CCRCC [5,6]. It is
clear that VHL gene encodes the pVHL, a component of E3
ubiquitin ligase, important in the ubiquitin-proteasome
protein degradation mechanism that targets hypoxia
inducible factors HIF-1α and HIF-2α [7].
HIF-1α is a heterodimeric transcription factor, and its
products regulate cell adaptation to hypoxic stress by
modulating a number of genes involved in vascular
growth and cellular metabolism, such as vascular
endothelial growth factors (VEGFs), erythropoietin or glu-
cose transporter-1 in physiologic and pathologic condi-
tions [8,9]. VEGFs include distinct signaling pathways for
angiogenesis and lymphangiogenesis and structurally
belong to the platelet derived growth factor family
(PDGF). Several closely related proteins have been discov-
ered (VEGF A-F) [1]. VEGF, sometimes referred to as
VEGF-A, has been shown to stimulate endothelial cell
mitogenesis and cell migration as well as vasodilatation
and vascular permeability [10].
VEGF-C is an essential chemotactic and survival factor
during embryonic and inflammatory lymphangiogenesis
and is predominantly expressed along with the VEGFR-3
receptor. There is evidence that tumor cells and tumor
associated macrophages secrete lymphangiogenic growth
factor VEGF-C, which induces development of nearby
lymphatic vessels, facilitating the access of tumor cells
into the vessels [11]. VEGF-C mRNA has been detected in
adult human kidney where it acts in an autocrine manner
to promote survival in podocytes [12], and is one of the
potential regulators of proximal tubular epithelial cell
communication with the peritubular capillary network
[13,14]. Literature data on the expression of VEGF-C in
CCRCC are controversial, mostly suggesting that VEGF-C
plays a little role in the progression of RCC [2].
Our previous studies demonstrated a heterogeneous
expression of VEGF-A in CCRCC with two distinct stain-
ing patterns being associated with different clinicopatho-
logic characteristics [15]. The aim of this study was to
expand our knowledge on the expression of VEGF-C, rec-
ognized to be involved in lymph vessel neoangiogenesis,
and to compare its value with the VEGF-A expression. Fur-
thermore, the expression of both angiogenic factors was
analyzed in comparison to HIF-1α, a regulatory factor of
angiogenic switch, and finally all study parameters were
compared with clinicopathologic characteristics of
CCRCC including patient survival.
Methods
Clinicopathologic data
This study included tumor specimens of CCRCC obtained
from patients undergoing nephrectomy at Department of
Urology, Rijeka University Hospital Center in Rijeka. All
cases were reviewed by two pathologists using WHO
tumor classification criteria [3]. Tissue microarrays (TMA)
were built from 94 archive formalin fixed and paraffin
embedded tumor tissues collected consecutively from
1989 to 1994. Clinicopathologic data obtained from
patient medical records and from files kept at Department
of Pathology, Rijeka University School of Medicine,
Rijeka, Croatia, included sex, age, overall survival, tumor
size, TNM stage, histological subtype and nuclear grade as
assessed using Fuhrman nuclear grading system [16].
Tissue microarray (TMA) construction
Hematoxylin and eosin stained tumor sections were used
to mark areas with highest nuclear grade avoiding areas of
necrosis. For all cases two donor blocks of each carcinoma
were used. Three tissue cores, each 1 mm in diameter,
were placed into recipient paraffin block using a manual
tissue arrayer (Alphelys, Plaisir, France). Normal liver tis-
sue was used for orientation. Cores were spaced at inter-
vals of 0.5 mm in the x- and y-axes. One section from each
TMA block was stained with hematoxylin and eosin for
morphological assessment. Serial sections were cut from
TMA blocks for immunhistochemical staining. Five-μm
thick sections were placed on adhesive glass slides (Capil-
lary Gap Microscope Slides, 75 μm, Code S2024, DakoCy-
tomation, Glostrup, Denmark), left to dry at 37°C
overnight and stored in the dark at +4°C.
Immunohistochemistry
Tumor samples were processed for immunohistology
analysis in a Dako Autostainer Plus (DakoCytomation
Colorado Inc, Fort Collins, CO, USA) according to the
manufacturer's protocol using Envision peroxidase proce-
dure (ChemMate TM Envision HRP detection kit K5007,
DakoCytomation, Glostrup, Denmark). Epitope retrieval
for VEGF-A, VEGF-C and Ki67 was achieved by immersing
slides in Tris-EDTA buffer (pH 9.0) and boiling for 10
minutes in water bath and for HIF-1α by immersing slides
in citrate buffer (pH 6.0) and boiling for 45 minutes. The
slides were allowed to cool for 45 minutes and then pre-
incubated with blocking solution containing normal goat
serum (DakoCytomation, Glostrup, Denmark) for 30
minutes. Primary antibodies, anti-HIF-1α (NB 100–131,Journal of Experimental & Clinical Cancer Research 2009, 28:40 http://www.jeccr.com/content/28/1/40
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Novus Biologicals, Littleton, CO, USA, dilution 1:3000,
30 min incubation), and anti-VEGF-A (C-1: sc-7269,
Santa Cruz Biotechnology, Santa Cruz, CA, USA, dilution
1:500, overnight incubation at 4°C) were monoclonal
antibodies of mouse origin, while anti-VEGF-C (H-190:
sc-9047, Santa Cruz Biotechnology, Santa Cruz, CA, USA,
dilution 1:100, overnight incubation at 4°C) was polyclo-
nal antibody of rabbit origin. Proliferative activity was
evaluated by detecting the Ki67 protein with monoclonal
antibody (clone MIB-1, DakoCytomation, Glostrup, Den-
mark, dilution 1:50, 30-min incubation). The binding of
the primary antibodies was assessed by incubation of sec-
ondary antibody (Dako REAL EnVision™/HRP, Rabbit/
Mouse (ENV) K5007, DakoCytomation, Glostrup, Den-
mark, 30-min incubation). A negative control consisting
of the omission of the primary antibody was performed
for each case.
Evaluation of immunostaining
The immunohistochemical staining results were evalu-
ated independently by two pathologists, without knowl-
edge of clinicopathologic data on each individual case.
No interobserver variability was found between the results
of the two independent observers. On statistical analysis,
the mean value of immunohistochemical staining of all
three tissue microarrays was used.
HIF-1α immunoreactivity was evaluated as percentage of
nuclear or cytoplasmic positivity by counting positive
tumor nuclei/cytoplasm at 500 tumor cells in tumor areas
with highest density of positive cells using ×400 magnifi-
cation and ISSA 3.1 software (Vams, Zagreb, Croatia). The
immunostaining of VEGF-A and C was evaluated as per-
centage of diffuse and perimembranous cytoplasmic
staining pattern in tumor cells. Smooth muscle cells in
vascular walls were used as internal control for VEGF-A,
cortical tubular cells for VEGF-C and glioblastoma cells
that were usually intensively positive when palisading
around necroses for HIF-1α. Ki67 index was also quanti-
fied by ISSA 3.1 software (Vams, Zagreb, Croatia) and
assessed by scoring 500 tumor cells at ×400 magnification
in the region with highest proliferative activity.
Statistical analysis
Statistical analysis was performed using Statistica 6.1 soft-
ware (StatSoft, Inc., Tulsa, OK, USA). Mann-Whitney U-
test was used to assess the significance of association of
HIF-1α, VEGF-A and -C with clinicopathologic data such
as nuclear grade, tumor size, Ki67 index and pathologic
stage. Pearson's correlation was used to determine associ-
ation between HIF-1α and VEGF-A or -C. The association
of immunohistochemical staining for HIF-1α, VEGF-A
and -C with patient survival was evaluated using Kaplan-
Meier method, and differences between groups were
tested by the log-rank test. Statistical differences with p
value less than 0.05 were considered significant.
Results
Immunoreacitivty of HIF-1α, VEGF-A and -C in clear cell 
renal cell carcinoma
HIF-1α
In normal renal tissue, there was diffuse cytoplasmic
staining of tubular cells and weak, nonspecific immunos-
taining in mesangial area in some glomeruli, which we
claimed as being negative for HIF-1α. In CCRCC, staining
was present in both tumor cell nuclei and/or cytoplasm
ranging from low to strong intensity (Fig. 1). Tumors
showed different proportions of positive nuclei (nHIF-
1α) and cytoplasm (cHIF-1α) for HIF-1α antibody
(median value 47.1, range 16.3–82.3 and median value
12.9, range 1.4–75, respectively).
VEGF-A and C
Immunohistochemical staining of VEGF-A was cytoplas-
mic, both in normal renal tissue and tumor cells, as we
described previously [15]. Immunohistochemical stain-
ing of VEGF-C was also cytoplasmic in normal renal tissue
and CCRCC showing heterogeneous staining of different
intensity and percentage of positive tumor cytoplasm as
well as perimembranous and/or diffuse staining pattern
(Fig. 1). Division according to percentage of perimembra-
nous or diffuse staining pattern turned out to be more
important than intensity and/or percentage of positive
tumor cytoplasm in relation to HIF-1α or clinicopatho-
logic parameters. The median value of perimembranous
staining pattern was 12.7% (range 0–94%) for VEGF-A
(pVEGF-A) and 46% (range 0–100%) for VEGF-C
(pVEGF-C). The median value of diffuse cytoplasmic pat-
tern was 10% (range 0–92%) for VEGF-A (dVEGF-A) and
26.3% (range 0–100%) for VEGF-C (dVEGF-C).
Association between HIF-1α, VEGF-A and -C
Nuclear HIF-1α demonstrated inverse correlation with
dVEGF-A (p = 0.002) and almost so with dVEGF-C (p =
0.053), and showed no association with perimembranous
staining pattern of either VEGF-A or -C. Cytoplasmic HIF-
1α correlated with both dVEGF-A (p < 0.001) and dVEGF-
C (p = <0.001), and also showed inverse correlation with
perimembranous staining pattern of VEGF-C (p < 0.001),
but not VEGF-A (Table 1).
Regarding association of VEGF-A and -C, Pearson's corre-
lation showed a relation of only diffuse staining pattern of
both proteins (p < 0.001, rp = 0.586) with no association
between the perimembranous staining patterns of the
mentioned growth factors.Journal of Experimental & Clinical Cancer Research 2009, 28:40 http://www.jeccr.com/content/28/1/40
Page 4 of 8
(page number not for citation purposes)
Association of HIF-1α, VEGF-A and -C with 
clinicopathologic parameters
There were 59 men and 35 women in the study. The
median value of tumor size was 6.3 (1.8–17.5) cm. The
Fuhrman nuclear grading distribution was as follows: 12
(12.8%) grade 1, 40 (42.6%) grade 2, 22 (23.4%) grade 3
and 20 (21.2%) grade 4 tumors. There were 71 (75.5%)
tumors limited to the kidney (pT1 and pT2) and 23
(24.5%) tumors with extrarenal expansion (pT3 and
pT4). The mean value of Ki67 proliferative index was 10.7
± 5.9%. Follow up was available for 87 patients and
ranged from 1 to 165 months (median 64 months). Sur-
vival time was calculated from the date of surgery to the
date of death or of the last follow up.
The expression of HIF-1α, VEGF-A and VEGF-C in carci-
noma cells was compared to tumor variables that repre-
sent prognostic factors in CRCC: nuclear grade, tumor
size, Ki67 proliferative index and pathologic stage (Table
2).
Nuclear HIF-1α and pVEGF-C expression was associated
with lower nuclear grade and smaller tumor size indicat-
ing better prognosis, while cHIF-1α together with dVEGF-
A and -C was associated with worse prognostic factors, i.e.
higher nuclear grade, larger tumor size and higher tumor
stage. There was no association of Ki67 index with either
protein analyzed.
Association of HIF-1α, VEGF-A and -C with patient survival
The association of immunohistochemical positivity for
HIF-1α, VEGF-A and VEGF-C and cumulative proportion
of patients surviving during the follow up are shown in
Figure 2.
The 5-year survival rates were significantly shorter for
patients whose tumors demonstrated low percentage of
nHIF-1α and pVEGF-C and high percentage of cHIF-1α
and dVEGF-A. Because tumor grading and staging are con-
sidered as major prognostic parameters in CCRCC, we
first analyzed their impact on postoperative survival. We
found a significant inverse association between survival
and tumor grading (p < 0.001) or staging (p = 0.003).
Univariate survival analysis showed nuclear grade, patho-
logic stage, nHIF-1α and cHIF-1α expression as well as
pVEGF-C and dVEGF-A to be significant predictive factors.
However, on multivariate analysis only nuclear grade
remained significant (relative risk was 3 and 95% confi-
dence interval 1.7–5.3), while pathologic stage (relative
risk was 1.5 and 95% confidence interval 1–2.4) together
with immunohistochemically analyzed proteins showed
no independent prognostic value.
Discussion
There is a very large body of evidence that VEGF-A and
related molecules such as VEGF-C and VEGF-D are potent
proangiogenic factors involved in tumor growth and
metastasis. Their intra-cell signaling pathway through spe-
cific receptors (VEGFRs) with tyrosine kinase activity pro-
vides targets for novel antiangiogenic designed drugs
[10,11,17]. Our study demonstrated the expression of
Immunohistochemical staining of HIF-1α, VEGF-A and VEGF- C in normal renal tissue (A-C) and clear cell renal cell carci- noma (CCRCC) (D-F) Figure 1
Immunohistochemical staining of HIF-1α, VEGF-A 
and VEGF-C in normal renal tissue (A-C) and clear 
cell renal cell carcinoma (CCRCC) (D-F). A homogene-
ous cytoplasmic staining of tubular cells and weak staining in 
glomerules was observed with HIF-1α (A), while VEGF-A 
and VEGF-C were positive in tubular cells, glomerular 
mesangium and interstitial macrophages (B and C). In 
CCRCC, HIF-1α immmunoreactivity was nuclear and/or 
cytoplasmic (D), while it was perimembranous and/or diffuse 
cytoplasmic for VEGF-A and VEFG-C (E and F). (magnifica-
tion ×200).
Table 1: Relation of HIF-1α to VEGF-A and VEGF-C
VEGF-A (%) VEGF-C (%)
pVEGF-A dVEGF-A pVEGF-C dVEGF-C
p1 rp
1 p1 rp
1 p1 rp
1 p1 rp
1
HIF-1α (%) nHIF-1α 0.535 0.068 0.002 -0.322 0.121 0.168 0.053 -0.209
cHIF-1α 0.094 -0.180 <0.001 0.526 <0.001 -0.629 <0.001 0.637
1Pearson's correlationJournal of Experimental & Clinical Cancer Research 2009, 28:40 http://www.jeccr.com/content/28/1/40
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VEGF-A and VEGF-C on tumor cells but also in the cyto-
plasm of cortical tubular cells, endothelium, mesangium
and macrophages, which is consistent with literature
reports [12-14,18]. Endothelial-cell maintenance through
regulated VEGF levels is crucial for glomerular function
[19]. VEGF-C promotes survival in podocytes acting in an
autocrine manner and both factors probably coordinate
the synchronous development of the tubular and vascular
architecture in the kidney required for the formation of
the functioning nephron [12-14].
Similar to our previous work [15] on whole tumor slices,
the heterogeneous expression of VEGF-A was also con-
firmed in TMA technique. Both angiogenic cytokines were
immunohistochemically detected as heterogeneous stain-
ing of different intensity and percentage of positive tumor
cells. Attention was especially focused on the pattern of
their cytoplasmic distribution, diffuse and/or perimem-
branous, as previously reported by Yildis et al. [20] and
Jacobsen et al. [21]. Jacobsen et al. believed that immuno-
histochemical VEGF expression near the cell membrane
was affected by storage time of paraffin embedded tumor
specimens and this type of VEGF expression was not fur-
ther evaluated [21]. According to our results, the percent-
age of perimembranous or diffuse staining pattern turned
out to be more important than the intensity and/or per-
centage of positive tumor cells in relation to HIF-1α or
pathological and clinical parameters relevant for disease
prognosis. Namely, diffuse and intensive cytoplasmic
VEGF-A and -C staining was associated with higher
nuclear grade, larger tumor size, higher tumor stage and
higher cHIF-1α.
There are not so many reports on VEGF-C expression in
CCRCC. Gunningham et al. found no significant up-regu-
lation of VEGF-C in neoplastic tissue compared with nor-
mal kidney [2]. According to Leppert et al., there was no
difference in the expression of VEGF-C among three main
types of RCC, although its main receptor VEGF-R3 was
overexpressed in CCRCC [22]. Also, a reduction of mRNA
VEGF-C in tumors was observed; however, it was not bio-
logically significant [2]. Recent results reported by Iwata et
al. [10] showed no significant relationship between VEGF-
C expression and clinicopathologic features of RCC, while
we found diffuse cytoplasmic and perimembranous distri-
bution to be associated with different clinicopathologic
parameters. Moreover, survival analysis showed a signifi-
cantly shorter overall survival in patients with tumors
exhibiting high diffuse cytoplasmic staining of VEGF-A/C.
This controversial but statistically consistent result may
suggest that detection of the cytoplasmic pattern in immu-
nohistochemical distribution of VEGF-C could possible
mean activation of various mechanisms in the progres-
sion of CCRCC.
Regarding HIF-1α expression in normal renal paren-
chyma, there was no positive reaction in glomeruli and no
nuclear positivity in normal tubular epithelium, as
reported by Di Cristofano et al. [23]. In CCRCC, the
expression was nuclear and/or cytoplasmic ranging from
low to strong intensity. Some authors report on protein
expression of HIF-1α in the tissue of RCC to be signifi-
cantly higher than in renal parenchyma adjacent to the
cancer [24]. The present study demonstrated correlation
of overexpression of all three proteins analyzed, i.e. HIF-
Table 2: Relation of HIF-1α, VEGF-A and VEGF-C to clinicopathologic parameters
Nuclear grade1 P value Tumor size (cm)1 p value Ki67 (%)1,2 P value Pathologic stage1 P value
1,2 3,4 < 7 ≥ 7 low high 1 2,3,4,
HIF-1α nHIF-1α 49.5 39 0.006 48.6 43.6 0.057 43.9 48.1 0.134 48.1 44.5 0.165
(%)
(16.3–82.3) (19.2–72.6) (27.9–73.9) (16.3–82.3) (16.3–72.4) (21.2–82.3) (27.9–73.9) (16.3–82.3)
cHIF-1α 11.4 18.7 0.006 11.3 17.5 0.009 14.6 11.6 0.246 11.4 16.6 0.023
(1.4–75) (5.2–59.5) (1.4–59.5) (2.9–75) (4.3–75) (1.4–46.5) (1.4–42.6) (2.9–75)
VEGF-A pVEGF-A 15 12.5 0.307 15 7.5 0.173 12.5 12.7 0.658 12.1 17.5 0.682
(%) (0.00–94) (0–75) (0–94) (0–75) (0–94) (0–75) (0–94) (0–75)
dVEGF-A 6.7 30 <0.001 6.7 16.7 0.015 10.6 10 0.652 6.3 11.7 0.027
(0–92.5) (0–90) (0–67.5) (0–92.5) (0–92.5) (0–83.3) (0–76.7) (0–92.5)
VEGF-C pVEGF-C 65 14 <0.001 64.2 27.9 0.007 45 55 0.913 61.3 33.3 0.042
(%) (0–100) (0–92.5) (0–100) (0–100) (0–100) (0–100) (0–100) (0–100)
dVEGF-C 18.5 37 0.004 18 37.1 0.007 25 26.3 0.516 20 30 0.109
(0–100) (0–100) (0–100) (0–100) (0–100) (0–100) (0–100) (0–100)
1Mann-Whitney U-test; median (range); 2cut-off is meanJournal of Experimental & Clinical Cancer Research 2009, 28:40 http://www.jeccr.com/content/28/1/40
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1α, VEGF-A and VEGF-C. Both nuclear and diffuse cyto-
plasmic positivity was statistically important in compari-
son with angiogenic factor expression and
clinicopathologic parameters. Nuclear HIF-1α expression
was associated with better prognosis in CCRCC, while
cHIF-1α was related to worse prognostic factors and
shorter patient survival. Recent literature data on the
expression of this regulatory factor are still controversial.
According to Kubis et al., up-regulation of the angiogenic
genes is due to an increase of HIF-1α protein levels in the
cytoplasm by inhibition of its targeting for proteosomal
degradation and not by regulation of nuclear import by its
nuclear location signal [25]. Lindgren et al. did not evalu-
ate nuclear staining and found the cHIF-1α levels in
patients with CCRCC to be significantly lower in locally
aggressive tumors than in localized tumors [26]. Klatte et
al. conclude that high nHIF-1α expression significantly
correlates with markers of apoptosis, VEGFs, and worse
survival as compared with patients with low nuclear
expression, which was demonstrated by multivariate anal-
ysis [24]. Di Cristofano et al. noted that in VHL inactivated
tumors, strong cytoplasmic positivity implied favorable
Kaplan-Meier cumulative survival analysis according to staining for nuclear and cytoplasmic HIF-1α, VEGF-A and VEGF-C Figure 2
Kaplan-Meier cumulative survival analysis according to staining for nuclear and cytoplasmic HIF-1α, VEGF-A 
and VEGF-C. The log-rank test showed significantly shorter overall survival in patients with tumors showing low nHIF-1α (p 
= 0.005) (A) and low pVEGF-C (p = 0.008) (D). The 5-year survival rate was 32% for patients whose tumors showed low nHIF-
1α vs. 65% for patients whose tumors showed high nHIF-1α (A); and 40% for patients whose tumors showed low pVEGF-C vs. 
61% for patients whose tumors showed high pVEGF-C (D). The log-rank test showed significantly shorter overall survival in 
patients with tumors showing high cHIF-1α (p = 0.018) (B) and high dVEGF-A (p = 0.024) (C). The 5-year survival rate was 
60% for patients whose tumors showed low cHIF-1α vs. 40% for patients whose tumors showed high cHIF-1α (B); and 59% for 
patients whose tumors showed low dVEGF-A vs. 40% for patients whose tumors showed high dVEGF-A (C).
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prognosis, while strong nuclear localization of HIF-1α
was associated with worse tumor specific survival [23].
Conclusion
Our results on nuclear expression of HIF-1α were quite
opposite to studies that describe nHIF-1α overexpression
as a marker of unfavorable prognosis in human cancer
[27-29]. Discrepancies between studies may reflect the
balance of multiple effects of HIF status with compart-
mentalization according to specific functional moments.
The HIF-1α mediated hypoxia response is therefore com-
plex and different pathways are likely to be activated in
different cell types.
In conclusion, the results obtained in this study highlight
the more aggressive subtype of CCRCC, associated with
overexpression of VEGF-A and cHIF-1α, which may have
some clinical implication. Additional studies are needed
to understand the significance of nHIF-1α expression
associated with better-differentiated tumors.
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